Pfizer sought to participate in the Subject Expert Committee consultations towards an emergency use authorisation for its Covid-19 vaccine. However, the company representatives have been unable to participate in the meetings because of extremely short notices of a few hours or less and time-zone limitations.
More than 2 million people have been diagnosed with coronavirus across the world, and the pharmaceutical industry is pulling out all stops to find potential treatments and vaccines for the global pandemic. According to the World Health Organization, there are now more than 70 potential vaccines under evelopment, with some already in clinical trials.
Vaccines Covishield and Covaxin work against SARS-CoV-2 variants Alpha, Beta, Gamma and Delta, while effectiveness tests against the Delta Plus variant is ongoing, the government said.
An important focus of the dry run will be on management of any possible adverse events following immunisation.
US-based global tech giants, including IBM, Amazon, Google and Microsoft, have partnered with the White House to "unleash the power of American supercomputing resources" for combating the novel coronavirus, President Donald Trump has said. From volunteering to manufacturing masks and ventilators to ramping up production of essential medical supplies and general items, the country's private sector have joined America's war against coronavirus in a big way, Trump said on Sunday, while launching a new public-private consortium organised by the White House, the department of energy and tech company IBM.
The company has developed detailed logistical plans and tools to support effective vaccine transport, storage, and temperature monitoring. Sohini Das and Ruchika Chitravanshi report.
The teams were from Gennova Biopharmaceuticals Ltd Pune, Biological E Ltd Hyderabad and Dr Reddys Laboratories Ltd Hyderabad.
"Zero is an unlikely figure. The virus is mutating and it is difficult to predict it's future behaviour,
The official expressed hope on the success of the five vaccines that are under different phases of trial in the country.
India expects 2.16 billion doses of Covid-19 vaccines between August and December, including the jabs that are currently in clinical trials, reports Sohini Das
'Prevention plus vaccination is what is going to take us into better territory by September or October.'
The CPI(M) leader said when the Nepali people overcome these obstacles, they shall create history by transforming this Himalayan Hindu kingdom into a modern democratic nation state based on democracy.
In September, Bharat Biotech aimed to supply 35 million doses, and take this up to 55 million by October. This is still less than what the Indian government expects from the company.
Dr Mishra further explained the effect of hybrid immunity on the vaccinated population and said that it is likely to give protection to people along with the Indian vaccines administered.
'Almost 70 per cent production time of a vaccine is dedicated to quality control, which is done through several hundred tests.'
The Reproduction number or Rt refers to how many people an infected person infects on average. In other words, it can tell how efficiently a virus is spreading.
'Rolling out the vaccine is not a major challenge in India.'
'Whoever owns the best chip industry will be the Saudi Arabia of the era of data,' predicts Rajeev Srinivasan.
This may include Rs 1,500 as a screening test for suspect cases and an additional Rs 3,000 for confirmation test, the guidelines said.
Providing data, it said UK's Public Health England has reported high vaccine effectiveness (87.9 per cent) against the B.1.617.2 variant, most reported in India, in an observational study (concluded on May 22, 2021).
'If you approached it with that level of aggression in 100 days, you would have vaccinated more than half of your country.' 'On a mass scale you will be able to eliminate that wave.'
The first two coaches that rolled out from the Railway Coach Factory in Kapurthala also have fixtures coated with titanium dioxide and the provision for plasma air equipment in AC ducts to sterilise interiors using ionised air. Railway Minister Piyush Goyal also indicated that the new coaches could be the new normal.
865 million Indian adults require vaccination.
During the webinar, 'COVID-19: Vaccination and Potential Return to Normalcy - If and When', Dr Hotez, an internationally-recognised physician-scientist in neglected tropical diseases and vaccine development, said that the COVID-19 vaccine rollout is "India's gift' to the world in combating the virus.
'At least half the population in UP has been infected.'
Unless public health is prioritised over swift re-opening, the chances are that a third wave will hit India sooner than we would like.
Weeks after the second wave peaked in many parts of the country, we are rapidly forgetting what happened to our hospitals, cautions Mihir S Sharma.
The search engine pays tribute to Rosalind Franklin best known as 'the woman who was not awarded the Nobel prize for the co-discovery of the structure of DNA'
So vaccinate employees and families, staff at home, rickshaw drivers, milkmen, service providers, shopkeepers and street vendors, says Naushad Forbes.
At $37 per dose, the Pfizer vaccine is much more expensive compared to $3 per dose for the Covishield.
According to an official statement, the FDA has determined that the Moderna COVID-19 vaccine has met the statutory criteria for issuance of an emergency use authorisation (EUA).
The Gam-COVID-Vac, called Sputnik V, is a two-part vaccine that includes two adenovirus vectors -- recombinant human adenovirus type 26 (rAd26-S) and recombinant human adenovirus type 5 (rAd5-S).
As India gets ready to roll out one of the largest vaccine programmes, billionaire Mukesh Ambani on Tuesday said his group is working with authorities to provide technology tools and backbone for mass inoculation against COVID-19. Ambani's telecom venture Jio was rolled out four years back, offering free voice calling and dirt-cheap data. Today, Jio is India's largest telecom operator with over 400 million users, each connected to the internet. At a Facebook event, Ambani said the government's digital push kept the country running even during the pandemic and is now helping in the rollout of one of the largest vaccination programmes.
Pioneering Indian American biochemist Har Gobind Khorana, who won the 1968 Nobel Prize for medicine, has died of natural causes in Concord, Massachusetts. Khorana, 89, who was Massachusetts Institute of Technology 's Alfred P Sloan Professor of Biology and Chemistry emeritus, died earlier this week. He won the Nobel Prize in 1968, sharing it with two others, for unravelling the nucleotide sequence of RNA and deciphering the genetic code.
'A third wave is possible, but we must try to restrict it to a low level by adopting all personal protection and public policy measures to prevent viral transmission, while speeding up vaccination.'
There are a number of vaccine candidates already in clinical trial and a few out of those candidates have completed phase 1/2 status, he said, adding that there are trials that will be going into phase three sometime at the end of July and then others will follow in the months of August, September and October.
'The world over, everybody is asking for the same medicines, same APIs, same KSMs.' 'However, there is just one supplier -- China -- for the entire world.'
Hari Shukla from Tyne and Wear said he feels it is his duty to receive his first of the two-dose vaccine, a moment UK Prime Minister Boris Johnson hailed as a "huge step forward" as Tuesday was dubbed "V-Day" or Vaccine Day in the UK.
The ICMR has approved over 200 labs (both public and private) for COVID-19 testing through-PCR machines.
'What is happening now is the virus is trying to survive inside us, and we are also trying to survive.' 'It is actually a fight. And the advantage the virus has is it multiplies very, very fast.' 'Within a second it can make 100 copies. Our cells are not like that.'
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances